Skip to main navigation

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

Kodiak Sciences

>> Site Menu

Our Company
Our Science
Our Products
Join Us
INVESTORS & MEDIA

News Releases

> News - Sub Nav

Press Releases

News Releases

May 10, 2022

Kodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

April 29, 2022

Kodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research Conferences

Additional Formats

PDF Version

March 1, 2022

Kodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

February 23, 2022

Kodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular Degeneration

Additional Formats

PDF Version

February 3, 2022

Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Additional Formats

PDF Version

January 3, 2022

Kodiak Sciences to Present at the 40th Annual J.P. Morgan Healthcare Conference

Additional Formats

PDF Version

December 16, 2021

Kodiak Sciences Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Additional Formats

PDF Version

November 9, 2021

Kodiak Sciences Announces Third Quarter 2021 Financial Results and Recent Business Highlights

Additional Formats

PDF Version

November 8, 2021

Kodiak Sciences to Present at Upcoming Conferences

Additional Formats

PDF Version

September 1, 2021

Kodiak Sciences Announces New Long-Term Performance Incentive Plan

Additional Formats

PDF Version

Pagination

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page
Last page

Displaying 1 - 10 of 86

Disclaimer

Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.

KODIAK SCIENCES INC.

1200 Page Mill Road
Palo Alto, CA 94304
United States of America

Kodiak Sciences GMBH
Dammstrasse 19
6300 ZUG
Switzerland

info@kodiak.com

Kodiak Sciences Valais GMBH
Rottenstrasse 5
3930 VISP
Switzerland

LinkedIn Twitter

Copyright © 2022 Kodiak Sciences Inc.